RESUMEN
OBJECTIVE: To investigate the protection effect of bifidobacterial adhesin for intestine ischemia/reperfusion (I/R) injury on gut barrier function in rat. METHODS: Seventy-two male SD rats were randomly divided into sham operation group (n = 24), I/R model group (n = 24) and pretreatment group of bifidobacterial adhesin (pretreatment group, n = 24). Six rats were anatomized at 6 h, 1 d, 4 d and 7d after inducing I/R model in each group, respectively. The pathological changes of the terminal ilea and the blood levels of TNFα, IL-6, IL-10, diamine oxidase (DAO), and the activity and content of D-lactic acid were observed. RESULTS: The blood levels of TNFα, IL-6, DAO and D-lactic acid in I/R model group were significantly higher than sham operation group at all time points (P < 0.05), while the blood level of IL-10 was no significantly change. The activity of IL-6 and DAO in pretreatment group was significantly lower than I/R model group at all time points (P < 0.05), the blood level of TNFα in pretreatment group was significantly lower than I/R model group at 1 d, the blood level of D-lactic was significantly lower than I/R model group at 4 d and 7 d (P < 0.05). Intestinal pathological damages were obviously milder in pretreatment group than I/R model group at all time points (Chiu's pathological scores: 6 h, 3.22 ± 0.22 vs 3.57 ± 0.20; 1 d, 3.77 ± 0.13 vs 3.90 ± 0.12; 4 d, 2.93 ± 0.23 vs 3.07 ± 0.21; 7 d, 2.10 ± 0.30 vs 2.22 ± 0.17, all P < 0.05). CONCLUSION: The pretreatment of bifidobacterial adhesin could protect the intestinal mucosa from I/R injury, and alleviate intestinal ischemic reperfusion injury.
Asunto(s)
Adhesinas Bacterianas/farmacología , Bifidobacterium , Mucosa Intestinal/efectos de los fármacos , Intestinos/patología , Daño por Reperfusión/prevención & control , Animales , D-Aminoácido Oxidasa/sangre , Interleucina-10/sangre , Interleucina-6/sangre , Mucosa Intestinal/metabolismo , Mucosa Intestinal/patología , Precondicionamiento Isquémico/métodos , Ácido Láctico/sangre , Masculino , Ratas , Ratas Sprague-Dawley , Factor de Necrosis Tumoral alfa/sangreRESUMEN
1. The role of angiotensin-converting enzyme (ACE) 2 is likely to balance the status of the renin-angiotensin system (RAS) by degrading angiotensin (Ang) II and generating Ang-(1-7). Earlier demonstrations that ACE2 is insensitive to ACE inhibitors prompted us to evaluate the effect of ACE inhibitors on ACE2 expression. 2. Liver fibrosis was induced in rats with 40% CCl(4) (2.5 mL/kg, s.c., twice per week). Half the rats were further treated with perindopril (2 mg/kg, p.o., daily). After 2 and 4 weeks treatment, ACE2 immunoreactivity was assessed by immunohistochemical staining, ACE2 protein expression was determined by western blot and mRNA expression of ACE2 and the Ang-(1-7) receptor Mas was determined by reverse transcription-polymerase chain reaction (RT-PCR). 3. As an in vitro study, hepatic stellate cells (HSC) were treated with AngII (0.1-10 micromol/L) alone or in combination with the synthesized peptide ACEI (Sigma-Aldrich). Western blot and RT-PCR were used to evaluate ACE2 expression and Mas mRNA levels. Furthermore, after treatment of HSC with the Mas antagonist A779 (1 micromol/L), the protein expression of connective tissue growth factor (CTGF) was detected to evaluate the interaction between AngII, ACEI and the ACE2-Mas axis. 4. Expression of both ACE2 mRNA and protein and Mas mRNA was markedly upregulated in both CCl(4)-injured rat liver and AngII-treated HSC. Further significant upregulation was observed following additional administration of ACEI. In addition, ACEI treatment of HSC inhibited AngII-induced overexpression of connective tissue growth factor and this effect was ameliorated by blockade of the Mas receptor with A779. 5. The findings of the present study suggest that ACE inhibitors are able to upregulate ACE2 under conditions of liver injury both in vivo and in vitro, which may indicate potential benefits of ACE inhibitors in the therapeutic treatment of liver fibrosis.
Asunto(s)
Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Cirrosis Hepática Experimental/tratamiento farmacológico , Cirrosis Hepática Experimental/enzimología , Peptidil-Dipeptidasa A/metabolismo , Perindopril/farmacología , Regulación hacia Arriba/efectos de los fármacos , Angiotensina II/análogos & derivados , Angiotensina II/farmacología , Enzima Convertidora de Angiotensina 2 , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Animales , Células Cultivadas , Factor de Crecimiento del Tejido Conjuntivo/metabolismo , Interacciones Farmacológicas , Células Estrelladas Hepáticas/efectos de los fármacos , Hígado/efectos de los fármacos , Hígado/enzimología , Cirrosis Hepática Experimental/metabolismo , Masculino , Fragmentos de Péptidos/farmacología , Perindopril/uso terapéutico , Proto-Oncogenes Mas , Proteínas Proto-Oncogénicas/antagonistas & inhibidores , Proteínas Proto-Oncogénicas/metabolismo , Ratas , Ratas Wistar , Receptores Acoplados a Proteínas G/antagonistas & inhibidores , Receptores Acoplados a Proteínas G/metabolismoRESUMEN
Cell migration and invasion are triggered by a number of chemoattractants that stimulate intracellular signaling pathways through regulating reorganization of the actin cytoskeleton. Rac1, an intracellular signal transducer, regulates a variety of cell functions, including the organization of the cytoskeleton, cell migration, and invasion. However, currently, very little is known about the roles of Rac1 in the cytoskeleton formation and invasion of human colorectal cancer cells. In our study, Rac1-shRNA was used to silence the Rac1 to reduce its expression specifically in Lovo cells. Our studies showed that RNA interference-mediated deletion of Rac1 strongly inhibited lamellipodia formation, cell migration, and invasion of Lovo cells in vitro. The deletion of Rac1 can serve as an alterative therapy to inhibit the invasion and metastasis of colorectal cancer cells.
Asunto(s)
Movimiento Celular , Neoplasias Colorrectales/genética , Interferencia de ARN , Proteína de Unión al GTP rac1/antagonistas & inhibidores , Adhesión Celular , Línea Celular Tumoral , Neoplasias Colorrectales/metabolismo , Neoplasias Colorrectales/patología , Citoesqueleto/metabolismo , Humanos , Microscopía Confocal , Seudópodos/metabolismo , Eliminación de Secuencia , Transfección , Proteína de Unión al GTP rac1/genética , Proteína de Unión al GTP rac1/metabolismoRESUMEN
OBJECTIVE: To study the role of activation of Rac1 in colorectal cancer cell migration and invasion. METHODS: Rac1 L61 plasmid and control plasmid were transfected into colorectal cancer cell line SW480 cells. Pull down assay by Western blotting was carried out to measure the amount of activited Rac1, and transwell permeable supports were used to assess the migration and invasion of SW480 cells with different activitivity of Rac1. RESULTS: The transfection ratio of SW480 cells was more than 80%. Pull down assay showed that the activited Rac1 was significantly higher in the SW480 cells transfected with Rac1 L61 plasmid than that in the control, and the amount of migrating and invasing SW480 cells transfected with Rac1 L61 plasmid in the Transwell permeable supports were significantly more than those in controls (migrating cell numbers: 43 +/- 9 vs. 22 +/- 5, P < 0.01; invasing cell numbers: 73 +/- 13 vs. 38 +/- 1, P < 0.01). CONCLUSION: The activation of Rac1 plays an important role in the migration and invasion of colorectal cancer cells.
Asunto(s)
Movimiento Celular , Neoplasias del Colon/patología , Proteína de Unión al GTP rac1/metabolismo , Línea Celular Tumoral , Neoplasias del Colon/metabolismo , Activación Enzimática , Vectores Genéticos , Proteínas Fluorescentes Verdes/genética , Proteínas Fluorescentes Verdes/metabolismo , Humanos , Invasividad Neoplásica , Plásmidos , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/metabolismo , Transfección , Proteína de Unión al GTP rac1/genéticaRESUMEN
OBJECTIVE: To investigate the signal transduction mechanism underlying the effects of angiotensin II (AngII) and aldosterone (Aldo) on nuclear factor-kappaB (NF-kappaB) DNA binding activity. METHODS: Sixty male Wistar rats were randomly divided into 4 groups: model group (Mo group), injected with CCl(4) subcutaneously twice a week to establish a model of hepatic fibrosis; perindopril group (Pe group), injected with CCl(4) subcutaneously twice a week and perfused with perindopril once a day; losartan group (Lo group), injected with CCl(4) subcutaneously twice a week and perfused with losartan once a day; and control group (Nc group), injected with olive oil subcutaneously. The rats were killed in batches respectively 4 and 6 weeks after and their livers were collected to undergo Masson staining and be observed by light microscope. Electrophoretic gel mobility shift assay (EMSA) was used to detect the NF-kappaB DNA binding activity in the liver tissues. Western blotting was used to detect the expression of IkappaBalpha in the plasma protein. Hepatic stellate cells (HSCs)-T6 were cultured and preincubated for 1 h or not with U0126 (an inhibitor of MAPK/ERK kinase MEK), irbesartan (an AT-1 receptor blocker), and N-acetylcysteine (NAC, an antioxidant), angiotensin-converting enzyme inhibitor (ACEI), or tumor necrosis factor alpha (TNFalpha) prior to exposure to AngII or Aldo for 0.5 h, 1 h, 2 h, and 4 h respectively. The binding activities of NF-kappaB DNA were observed by EMSA. The expression of IkappaBalpha protein was detected with Western blotting. Histochemistry was used to detect the expression of NF-kappaB p65. RT-PCR was used to detect the expression of TNFalpha mRNA in HSC-T6 cells. RESULTS: The binding activity to NF-kappaB of the liver tissues was the strongest in the Mo group, followed by the Pe and Lo groups and Nc group. The IkappaBalpha expressions in liver tissues 4 and 6 weeks after the beginning of experiment in the Pe and Lo groups were significantly stronger than that in the Mo group (both P < 0.05). 0.5 hour after the intervention of AngII the DNA binding activity of the HSCs began to increase and peaked 1 hour later and then gradually decreased. The increase of NF-kappaB activity induced by AngII could be inhibited by irbesartan, ACEI and NAC pretreatment and could not be inhibited by U0126 pretreatment. Combined action of AngII and TNFalpha significantly increased the NF-kappaB DNA binding activity. The IkappaBalpha expression began to decrease 0.5 hour after the intervention of AngII and reached the lowest value 2 hours after. The expression of IkappaBalpha protein was increased by ACEI (P < 0.05), irbesartan and NAC (both P < 0.01). EMSA showed that 0.5 hour after the intervention of Aldo the DNA binding activity began to be increased and peaked by 1 hour and then began to be decreased. NAC, but not U0126 partly inhibited the increased of NF-kappaB activity induced by Aldo. Combined action of Aldo and TNFalpha significantly increased the NF-kappaB activity. Aldo increased the expression of IkappaBalpha protein in the HSCs at different time points (all P < 0.05). 0.5 hour after the AngII intervention the IkappaBalpha protein expression began to decrease and reach the lowest value 1 hour later and then began to increase 2 hours later. the IkappaBalpha protein expression was significantly decreased in the NAC and NAC+ Aldo intervention groups (both P < 0.05). There was no significant difference in IkappaBalpha protein expression between the Aldo intervention group and U0126 + Aldo, TNFalpha, and Aldo + TNFalpha treatment groups (all P > 0.05). Before stimulation, NF-kappaB was expressed in the plasma of HSCs, however, after the stimulation of AngII or Aldo for 1 hour it was expressed in the nuclei, and then transferred from the nuclei to the plasma 4 hours after the stimulation. However, little nuclear transfer was observed after pretreatment of NAC followed by AngII or Aldo intervention. The TNFalpha mRNA expression was significantly increased in the AngII and Aldo treatment groups in comparison with the control group (both P < 0.05). The TNFalpha mRNA expression was significantly weaker in the irbesartan + AngII, NAC + AngII, and ACEI groups in comparison with the AngII group (all P < 0.05). CONCLUSION: Stimulation of NF-kappaB activity mediates hepatic fibrosis induced by intrahepatic renin-angiotensin-aldosterone system (RAAS).
Asunto(s)
Aldosterona/farmacología , Angiotensina II/farmacología , Cirrosis Hepática/metabolismo , FN-kappa B/metabolismo , Animales , Proteínas de Unión al ADN/metabolismo , Proteínas I-kappa B/biosíntesis , Hígado/patología , Masculino , Inhibidor NF-kappaB alfa , Ratas , Ratas Wistar , Transducción de SeñalRESUMEN
OBJECTIVE: To study the PCR amplification, cloning and protein expression of interferon-inducible transmembrane protein-1 (IFITMP-1) gene. METHODS: With the cDNA fragment containing IFITMP-1 gene as template, IFITMP-1 gene was amplified using Pfu enzyme by means of PCR. After EcoRI and HindIII digestion, the target gene fragment was linked to pUCm-T plasmid and sequenced. The IFITMP-1 gene was cloned into pET-Trx protein expression plasmid, and the condition for protein expression was optimized. RESULTS: The length of the PCR product of IFITMP-1 gene-containing cDNA fragment was about 1000 bp. The IFITMP-1 gene was successfully inserted into pUCm-T plasmid with correct sequence and cloning of the IFITMP-1 gene into the pET-Trx protein expression plasmid was achieved. Expression of the fusion protein of pUCm-T plasmid and IFITMP-1 gene was detected after IPTG induction. CONCLUSION: Successful amplification and cloning of the IFITMP-1 gene and its protein expression may facilitate further study of the role of IFITMP-1 gene in colorectal cancer.
Asunto(s)
Neoplasias Colorrectales/genética , Neoplasias Colorrectales/metabolismo , Interferones/farmacología , Proteínas de la Membrana/biosíntesis , Antígenos de Diferenciación , Clonación Molecular , Humanos , Proteínas de la Membrana/genética , Reacción en Cadena de la Polimerasa , Proteínas Recombinantes de Fusión/biosíntesis , Proteínas Recombinantes de Fusión/genéticaRESUMEN
OBJECTIVE: It is known that intrahepatic renin-angiotensin-aldosterone system (RAAS) plays a key role in liver fibrogenesis. Aldosterone (Aldo), the principal effector molecule of the RAAS, exerts local effects on cell growth and fibrogenesis. However, the signal transduction mechanisms underlying the effects of Aldo on hepatic fibrogenesis remain to be fully elucidated. The present study aims to investigate the signal transduction mechanism underlying the effects of Aldo on extracellular signal-regulated kinase 1/2 (ERK1/2), early growth response-1 (EGR-1) and on the platelet-derived growth factor-B (PDGF-B). METHODS: In vitro, hepatic stellate cell (HSC)-T6 cell line was treated with Aldo for 10 min, 0.5 h, 1 h, 2 h and 3 h. Protein expression of phospho-p42/44 was detected by Western blot. In addition, HSC-T6 were preincubated for 1 h or not at all with U0126 (an inhibitor of the MAPK/ERK kinase), and antioxidant-N-acetylcysteine (NAC) prior to exposure to Aldo for the indicated times. Protein expressions of phospho-p42/44 and PDGF-B were measured by Western blot. DNA biding activity of EGR-1 was analyzed by electrophoretic gel mobility shift assay (EMSA). By means of immunohistochemistry, expression of PDGF-B was detected. RESULTS: Aldo induced phospho-p42/44 expression could be abrogated by U0126; NAC did not inhibit phospho-p42/44 expression. Gel shift study showed that stimulation of HSC by Aldo markedly increased the EGR-1 DNA binding activity, which was abrogated by U0126, reaching a maximum at 60 minutes, and then declined progressively. NAC did not reduce the EGR-1 activity. Aldo increased the PDGF-B protein level in HSC, which was not attenuated by NAC and U0126. CONCLUSIONS: Stimulation of HSC by Aldo results in activation of EGR-1 via ERK1/2 pathway, leading to up-regulation of PDGF-B expression.
Asunto(s)
Aldosterona/farmacología , Proteína 1 de la Respuesta de Crecimiento Precoz/biosíntesis , Hepatocitos/metabolismo , Proteínas Proto-Oncogénicas c-sis/biosíntesis , Transducción de Señal , Línea Celular , Proteína 1 de la Respuesta de Crecimiento Precoz/genética , Hepatocitos/citología , Humanos , Proteína Quinasa 3 Activada por Mitógenos/biosíntesis , Proteína Quinasa 3 Activada por Mitógenos/genética , Proteínas Proto-Oncogénicas c-sis/genéticaRESUMEN
AIM: To observe competitive inhibition of adherence of enterotoxigenic Escherichia coli (ETEC), enteropathogenic Escherichia coli (EPEC) and Clostridium difficile (C. difficile) to intestinal epithelial cell line Lovo by purified adhesin of Bifidobacterium adolescentis 1027 (B. ado 1027). METHODS: The binding of bacteria to intestinal epithelial cell line Lovo was counted by adhesion assay. The inhibition of adherence of ETEC, EPEC and C. difficile to intestinal epithelial cell line Lovo by purified adhesin of B. ado 1027 was evaluated quantitatively by flow cytometry. RESULTS: The purified adhesin at the concentration of 10 microg/mL, 20 microg/mL and 30 microg/mL except at 1 microg/mL and 5 microg/mL could inhibit significantly the adhesion of ETEC, EPEC and C. difficile to intestinal epithelial cell line Lovo. Moreover, we observed that a reduction in bacterial adhesion was occurred with increase in the concentration of adhesin, and MFI (Mean fluorescent intensity) was decreased with increase in the concentration of adhesin. CONCLUSION: The purified adhesin of B. ado 1027 can inhibit the adhesion of ETEC, EPEC and C. difficile to intestinal epithelial cell line Lovo in a dose-dependent manner.
Asunto(s)
Adhesinas Bacterianas/farmacología , Adhesión Bacteriana/efectos de los fármacos , Clostridioides difficile/fisiología , Enterocolitis Seudomembranosa/prevención & control , Infecciones por Escherichia coli/prevención & control , Escherichia coli/fisiología , Bifidobacterium , Línea Celular , Clostridioides difficile/patogenicidad , Diarrea/prevención & control , Escherichia coli/patogenicidad , Citometría de Flujo , Humanos , Mucosa Intestinal/citología , Mucosa Intestinal/microbiología , VirulenciaRESUMEN
AIM: To reduce the incidence of postoperative anastomotic leak, stenosis, gastroesophageal reflux (GER) for patients with esophageal carcinoma, and to evaluate the conventional method of esophagectomy and esophagogastroplasty modified by a new three-layer-funnel-shaped (TLF) esophagogastric anastomotic suturing technique. METHODS: From January 1997 to October 1999, patients with clinical stage I and II (IIa and IIb) esophageal carcinoma, which met the enrollment criteria, were surgically treated by the new method (Group A) and by conventional operation (Group B). All the patients were followed at least for 6 months. Postoperative outcomes and complications were recorded and compared with the conventional method in the same hospitals and with that reported previously by McLarty et al in 1997 (Group C). RESULTS: 58 cases with stage I and II (IIa and IIb) esophageal carcinoma, including 38 males and 20 females aged from 34 to 78 (mean age: 57), were surgically treated by the TLF anastomosis and 64 by conventional method in our hospitals from January 1997 to October 1999. The quality of swallowing was improved significantly (Wilcoxon W=2 142, P=0.0 001) 2 to 3 months after the new operation in Group A. Only one patient had a blind anastomatic fistula diagnosed by barium swallow test 2 months but healed up 3 weeks later. Postoperative complications occurred in 25 (43 %) patients, anastomotic stenosis in 8 (14 %), and GER in 13 (22 %). The incidences of postoperative anastomotic leak, stenosis and GER were significantly decreased by the TLF anastomosis method compared with that of conventional methods (chi(2)=6.566, P=0.038; chi(2)=10.214, P=0.006; chi(2)=21.265, P=0.000). CONCLUSION: The new three-layer-funnel-shaped esophagogastric anastomosis (TLFEGA) has more advantages to reduce postoperative complications of anastomotic leak, stricture and GER.
Asunto(s)
Anastomosis Quirúrgica/métodos , Neoplasias Esofágicas/cirugía , Adulto , Anciano , Neoplasias Esofágicas/patología , Esófago/cirugía , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Complicaciones Posoperatorias , Estómago/cirugíaRESUMEN
During the Evolution, effected by select pressure or nature mutation, the compositions of bacteria genomes is various. And many experiences prove that the genes between leading strand and lagging strand is distinctly in copy, transcription and repair. Some scholars presume that the bases distribution is difference between the two strand, to verify the guess, we using the technology of bioinformatics, compare the base usage between the DNA double strand in 17 species bacteria. The result show: 1. there is same bases usage frequency in coding sequence between leading strand and lagging strand 2. There also same bases usage frequency in first codon, second codon and third codon. It suggest that there is a equilibrium between the two strand by the effect of select pressure and nature mutation.
Asunto(s)
Bacterias/genética , Codón/genética , ADN Bacteriano/genética , Bases de Datos de Ácidos Nucleicos , Evolución Molecular , Genes Bacterianos/genética , Genoma Bacteriano , Mutación , Nucleótidos/genética , Selección GenéticaRESUMEN
OBJECTIVE: To investigate the angiogenesis in human colorectal carcinoma and its modulation by p53 and K-ras gene. METHODS: The positive rate of p53 and K-ras gene mutation, the expression of vascular endothelial growth factor (VEGF) and microvessel density in 68 cancer tissue, peritumoral tissue samples and 20 normal controls were studied by PCR-SSCP and immunohistochemical methods. RESULTS: The positive rate of p53 and K-ras gene mutation and the expression of VEGF in cancer tissue (47.1%, 32/68; 44.1%, 30/68; 55.9%, 38/68) were significantly higher than in peritumoral tissue (13.2%, 9/68; 7.4%, 5/68; 11.8%, 8/68). p53, K-ras gene mutation and the expression of VEGF were not detected in 20 normal tissue. The expression of VEGF was closely related with the angiogenesis and metastasis of colorectal carcinoma (r = 0.820, P < 0.01). VEGF expression correlated with both p53 and K-ras gene mutation (P < 0.01). CONCLUSIONS: p53 and K-ras gene upregulated the expression of VEGF. p53 and K-ras gene might play an important role in modulating tumor angiogenesis.
Asunto(s)
Neoplasias Colorrectales/irrigación sanguínea , Regulación Neoplásica de la Expresión Génica , Genes p53/genética , Genes ras/genética , Neovascularización Patológica/genética , Factor A de Crecimiento Endotelial Vascular/biosíntesis , Adulto , Anciano , Anciano de 80 o más Años , Neoplasias Colorrectales/genética , Neoplasias Colorrectales/metabolismo , Femenino , Humanos , Masculino , Persona de Mediana Edad , Mutación , Regulación hacia ArribaRESUMEN
OBJECTIVE: The aim of the present study was to determine the effects of angiotensin-converting enzyme inhibitor (ACE-I) and angiotensin II type 1 receptor (AT-1 receptor) blocker on the progression of rat hepatic fibrosis induced by CCl4. METHODS: 60 male wistar rats weighting about 250 g were divided into 4 groups. Model group (Mo): The rats were injected with 40% CCl(4) 0.25 ml/100 g subcutaneously three times a week. Perindopril group (Pe): The rats were injected with 40% CCl(4). Perindopril, equivalent to 2 mg x kg(-1) x d(-1), was given i.g. Losartan group (Lo): The rats were injected with 40% CCl(4). Losartan, equivalent to 50 mg x kg(-1) x d(-1), was given i.g. Control group (Nc): the rats were injected with olive oil only. After 4, 6 weeks, morphological examination was based on microscopy. RT-PCR was utilized to detect gene expression of AT-1 receptor in the liver. Meanwhile, the protein expressions of AT-1 receptor, TGF-beta1 and PDGF-BB in liver tissue were examined by Western blot. The activity of matrix metalloproteinase-2 (MMP-2) was assessed by zymography. Serum laminin (LN) and hyaluronic acid (HA) were measured using radioimmunoassays. RESULTS: RT-PCR and Western blot revealed that there was a up-regulation in AT-1 receptor expression in model group compared with control group. Both of perindopril and losartan treatment significantly reduced mean fibrosis score, messenger RNA and protein levels of AT1 receptor, protein levels of TGF-beta1 and PDGF-BB, Serum levels of HA and LN, and MMP-2 activity. CONCLUSION: These results suggest that angiotensin IImay play an important role in fibrosis of liver. Perindopril and losartan may have inhibiting effects on CCl(4)-induced hepatic fibrogenesis of rat.
Asunto(s)
Bloqueadores del Receptor Tipo 1 de Angiotensina II/uso terapéutico , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Cirrosis Hepática Experimental/metabolismo , Animales , Intoxicación por Tetracloruro de Carbono , Ácido Hialurónico/sangre , Laminina/sangre , Cirrosis Hepática Experimental/inducido químicamente , Cirrosis Hepática Experimental/patología , Losartán/uso terapéutico , Masculino , Metaloproteinasa 2 de la Matriz/metabolismo , Perindopril/uso terapéutico , Ratas , Ratas WistarRESUMEN
With more and more genome have been completely sequenced, scientists find the Partial Rule 2 (PR2) in entire single strand that A approximately equal to T, G approximately equal to C. But from the scope of thousands to hundreds of thousand bases, A not = T, G not = C. From the view of math, if the mutational rate of one strand is equal to others, it could be proved that A approximately equal to T, G approximately equal to C, but from the view of experience, that premise doesn't exist, so the solution of the problem needs the deeply combination of biology and math.
RESUMEN
OBJECTIVE: To investigate adriamycin (Adr) uptake and distribution features in multidrug-resistant LoVo/Adr cells and explore the drug-resistance mechanism of the cells. METHODS: Adr uptake in LoVo/Adr cells was observed by flow cytometry and the distribution of the drug examined by fluorescence microscope. Immunohistochemical method was employed to detect the expression of P-glycoprotein (P-gp) by the cells. RESULTS: In comparison with that in LoVo/Adr cells, Adr level in LoVo cells was significantly higher, but after treatment with verapamil, the former cells showed an increased Adr level. Adr distributed mainly in the nucleus in the drug-sensitive LoVo cells, with only a small quantity in the cytoplasm, while in multidrug-resistant LoVo/Adr cells, significantly reduction of Adr quantity in the nucleus and relative increase in the cytoplasm were observed. In response to verapamil treatment, the Adr uptake in LoVo/Adr cells increased and the distribution of the drug was similar to that in sensitive cells. P-gp expression was positive in LoVo/Adr cells, while negative in LoVo cells. CONCLUSION: Abnormal Adr uptake and distribution in drug-resistant cells is related to P-gp expression which is one of the mechanisms for multidrug resistance.
Asunto(s)
Antineoplásicos/farmacocinética , Doxorrubicina/farmacocinética , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/biosíntesis , Resistencia a Múltiples Medicamentos , Resistencia a Antineoplásicos , Humanos , Inmunohistoquímica , Células Tumorales Cultivadas/efectos de los fármacos , Células Tumorales Cultivadas/metabolismo , Verapamilo/farmacologíaRESUMEN
OBJECTIVE: To study the expression difference of CPP32 in multidrug-resistant (mdr) tumor cells and their parent cells and to understand the possible effect of CPP32 in apoptosis induction in the 2 cell lines. METHODS: Sequence analysis of CPP32 mRNA extracted form mdr gastric cancer cell line SGC7901/VCR08 and naive cell line SGC7901 was performed by means of reverse transcriptase-polymerase chain reaction (RT-PCR), and the protein expression of CPP32 in the 2 cell lines assayed by way of Western blotting. RESULTS: The expressions of CPP32 mRNA was comparable in the 2 cell lines, and sequence analysis found consistent sequence of CPP32 in both cell lines with previous report. No differences was identified in the protein expression, either. CONCLUSION: The apoptosis resistance of mdr cells is not related to the abnormality of CPP32 but the upstream of caspase, the fact of which indicates promising prospect of the research on reversion of mdr cells using CPP32 as target.
Asunto(s)
Caspasas/biosíntesis , Resistencia a Múltiples Medicamentos/fisiología , Apoptosis/fisiología , Caspasa 3 , Humanos , Células Jurkat , ARN Mensajero/biosíntesis , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Análisis de Secuencia de ADN , Células Tumorales CultivadasRESUMEN
OBJECTIVE: To express the original human Fab antibody phage display library with positive recombined bacterium XL1-blue-Pcomb3 and identify its specific binding activity with colorectal cancer cells in vitro after screening with human colorectal cancer-related antigens. METHOD: The recombination rate of Fd fragment of the heavy chain and insertion of kappa chain of the antibodies was determined with PCR, and the original Fab library was expressed. The antigens were extracted from 3 sensitized colorectal cancer tissues previously used for construction of the original Fab library and from 13 non-sensitized colorectal cancer tissues, along with the antigens from LoVo, HT-29 and LS-174T cells cultured in vitro. The original Fab antibody library was screened with the 3 groups of mixed antigens derived in preceding procedure and 3 tertiary Fab antibody libraries were obtained, which were then mixed in equal volume for subsequent tests of binding activity with human colorectal cancer tissues and cells in vitro using enzyme-linked immunosorbent assay (ELISA) and immunohistochemical staining. Specimens of gastric and esophageal carcinomas and normal intestinal mucosa, together with liver cancer cells and gastric cancer cells were utilized as control. RESULT: The recombination rate of Fd and kappa chain were 40 % and 70 % respectively, and the rate of their simultaneous insertion into Pcomb3 vector was 28%. The capacity of library for Fab fragment genes was 2.1x10(6), and the original antibody libraries screened with the 3 groups of mixed antigens were enriched to varied degrees, which all displayed relatively specific binding activity with human colorectal cancer tissue and cells in vitro. CONCLUSION: Colorectal cancer-related antibody Fab fragments are obtained through screening phage display library, which show relatively specific binding activity with human colorectal cancer tissues and cells.
Asunto(s)
Anticuerpos Antineoplásicos/biosíntesis , Neoplasias Colorrectales/inmunología , Fragmentos Fab de Inmunoglobulinas/biosíntesis , Anticuerpos Antineoplásicos/genética , Anticuerpos Antineoplásicos/inmunología , Especificidad de Anticuerpos , Antígenos de Neoplasias/inmunología , Humanos , Fragmentos Fab de Inmunoglobulinas/genética , Fragmentos Fab de Inmunoglobulinas/inmunología , Biblioteca de PéptidosRESUMEN
OBJECTIVE: To observe the effect of protein kinase C (PKC) on the multidrug resistance of multidrug-resistant colorectal cancer LoVo/Adr cells and explore the mechanism. METHODS: The changes of PKC activity in LoVo/Adr cells in response to treatment with staurosporine (SP) and phorbol-12-myristate-13-acetate (PMA) were detected by way of 32P incorporation. The effect of PKC on adriamycin uptake in LoVo/Adr cells was detected by flow cytometry. Reverse transcriptase-PCR was utilized to observe the effect of PKC on mdr1 gene expression. RESULTS: PMA evinced bi-directional regulation of PKC activity in LoVo/Adr cells, and SP significantly inhibited membrane and cytosol fraction of PKC activity. Preincubation with PMA for 30 min caused the uptake of adriamycin to decrease significantly, but when the preincubation was prolonged to 24 h, significant increase occurred in adriamycin uptake. Neither PMA nor SP, however, could affect the expression of mdr1 gene. CONCLUSION: PKC regulates multidrug resistance of the cells through mechanisms other than regulation of mRNA level of mdr1 gene.
Asunto(s)
Neoplasias Colorrectales/enzimología , Resistencia a Múltiples Medicamentos/fisiología , Proteína Quinasa C/metabolismo , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Neoplasias Colorrectales/patología , Doxorrubicina/farmacocinética , Interacciones Farmacológicas , Regulación de la Expresión Génica , Humanos , Proteína Quinasa C/efectos de los fármacos , Estaurosporina/farmacología , Acetato de Tetradecanoilforbol/farmacología , Células Tumorales CultivadasRESUMEN
OBJECTIVE: To study the effect of Bifidobacterial adhesin on proliferation and apoptosis of intestinal epithelial cell induced by lypopolysaccharide (LPS) and H(2)O(2) in vitro. METHODS: With (3)H-TdR incorporation method, flow cytometry and fluorochrome staining, the proliferation and apoptosis of intestinal epithelial cells induced by LPS and H(2)O(2) in vitro were studied. RESULTS: LPS at the dose of 100 microg/L effectively stimulated the proliferation and apoptosis of cells, whereas H(2)O(2) at the dose of 200 micromol/L obviously restrained the proliferative ability while enhanced the apoptosis of the cells. Fluorochrome staining showed cell shrinkage, nuclear condensation and fragmentation under microscope. After treatment with Bifidobacterial adhesin, the cell proliferation and apoptosis decreased significantly in LPS group, and in H(2)O(2) group, cell apoptosis was significantly decreased. CONCLUSIONS: Bifidobacterial adhesin can protect intestinal epithelial cells from the damage by LPS and H(2)O(2), and maintain the balance between the proliferation and apoptosis of the cells.
Asunto(s)
Adhesinas Bacterianas/farmacología , Apoptosis/efectos de los fármacos , Bifidobacterium/fisiología , Citoprotección , Peróxido de Hidrógeno/toxicidad , Mucosa Intestinal/efectos de los fármacos , Lipopolisacáridos/toxicidad , División Celular/efectos de los fármacos , Línea Celular Tumoral , Citometría de Flujo , Humanos , Mucosa Intestinal/citologíaRESUMEN
OBJECTIVE: To explore the mechanism that Helicobacter pylori (H. pylori) infection can induce adenocarcinoma in Mongolian gerbil model with long-term H. pylori infection. METHODS: Mongolian gerbil model with long-term H. pylori infection was established by inoculation H. pylori NCTC 11637 strain, and immunohistochemical straining and in situ hybridization were employed to observe changes in gastric mucosal cell proliferation due to H. pylori infection. RESULTS: Mongolian gerbil model with long-term H. pylori infection was successfully established. Immunohistochemical staining of 5'-bromodeoxyuridine (BrdU) and proliferating cell nuclei antigen (PCNA) showed that H. pylori infection induced the increase in gastric mucosal cell proliferation (P<0.05), and in situ hybridization of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) revealed elevated expressions of EGF mRNA and EGFR mRNA with time passage after H. pylori infection (P<0.05). CONCLUSION: H. pylori inoculation can induce abnormality in gastric mucosal cell proliferation, which is instrumental for the progression from chronic gastritis to glandular atrophy, intestinal metaplasis and ultimately to atypical hyperplasia. The abnormal expressions of EGF and EGFR may be the key element for abnormality of gastric mucosal cell proliferation.
Asunto(s)
Infecciones por Helicobacter/patología , Helicobacter pylori , Mucosa Intestinal/microbiología , Animales , Bromodesoxiuridina/metabolismo , División Celular/fisiología , Modelos Animales de Enfermedad , Gerbillinae , Infecciones por Helicobacter/microbiología , Mucosa Intestinal/patología , Masculino , Antígeno Nuclear de Célula en Proliferación/metabolismoRESUMEN
In the past 20 years we have performed endoscopic removal of colorectal polyps in 4 000 cases, and thorough histological examination of the removed polyps identified 121 cases of early-stage malignant polyp. According to the depth of malignant invasion and whether malignant remnants were present after the initial surgical removal, conservative treatment or radical operation was implemented. During the follow-up study, endoscopy was performed once each year in all the patients with malignancies. No recurrence was found in the 33 patients with mucosa cancer or in the 27 patients with type I submucosa cancer who did not receive radical operation due to absence of malignant remnants or in the 38 patients with type II submucosa cancer who had the radical operation. Relapse occurred in 1 patient with malignant remnant and in another 3 cases of type II submucasa cancer without radical operation.